Literature DB >> 33906046

A novel Hsp70 inhibitor specifically targeting the cancer-related Hsp70-Bim protein-protein interaction.

Ziqian Wang1, Ting Song2, Zongwei Guo3, Laura B Uwituze1, Yafei Guo3, Hong Zhang3, Hang Wang3, Xiaodong Zhang1, Hao Pan1, Tong Ji1, Fangkui Yin1, Sheng Zhou1, Jian Dai1, Zhichao Zhang4.   

Abstract

Targeting cancer-related Hsp70-Bim protein-protein interactions (PPIs) offers a new strategy for the design of Hsp70 inhibitors. Herein, we discovered a novel Hsp70 inhibitor, S1g-6, based on the established BH3 mimetics. S1g-6 exhibited sub-μM binding affinity toward Hsp70 and selectively disrupted Hsp70-Bim PPI. The target specificity of S1g-6in situ was validated by affinity-based protein profiling, co-immunoprecipitation, and cell-based shRNA assays. S1g-6 specifically antagonized the ATPase activity of Hsp70 upon recruiting Bim and showed selective apoptosis induction in some cancer cell lines over normal ones through suppression of some oncogenic clients of Hsp70, representing a new class of antitumor candidates. Hsp70-Bim PPI exhibited cancer-dependent role as a potential anti-cancer target.
Copyright © 2021 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antitumor candidate; Cancer-related target; Hsp70 inhibitor; Hsp70-bim PPI

Year:  2021        PMID: 33906046     DOI: 10.1016/j.ejmech.2021.113452

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Cytoplasmic proteotoxicity regulates HRI-dependent phosphorylation of eIF2α via the Hsp70-Bag3 module.

Authors:  Shivani Patel; Santosh Kumar; Simone Baldan; Arkadi Hesin; Julia Yaglom; Michael Y Sherman
Journal:  iScience       Date:  2022-04-22

Review 2.  Advances in the study of HSP70 inhibitors to enhance the sensitivity of tumor cells to radiotherapy.

Authors:  Sihan Du; Ying Liu; Yuan Yuan; Yuran Wang; Yanfang Chen; Shuai Wang; Yuhua Chi
Journal:  Front Cell Dev Biol       Date:  2022-08-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.